Urine Raman Spectroscopy for Non-Invasive COVID-19 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a urine-based screening test to diagnose and understand the renal effects of COVID-19, as existing methods lack validation and are costly, invasive, or require advanced technology, and current studies have limitations in detecting renal viral infection.
Innovation Solution
A method using Raman spectroscopy and computational analysis to detect COVID-19 by analyzing the 'molecular fingerprint' in urine samples, which represents systemic metabolic, inflammatory, and immunologic reactions, without detecting SARS-CoV-2 virus or viral components, through principal component analysis and discriminant analysis of principal components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If urine-based screening tests are developed to diagnose COVID-19 renal effects, then diagnostic accessibility and cost-effectiveness are improved, but detection precision and validation reliability are worsened due to lack of established methodologies
Solution Approach 1:
The patent replaces complex mechanical/biological detection systems (renal biopsies, autopsy-derived samples requiring multiple validation methods) with a non-invasive optical detection system (Raman spectroscopy). This substitution enables urine-based screening to achieve diagnostic precision comparable to invasive methods while dramatically improving accessibility and reducing cost.
Solution Approach 2:
The patent introduces urine as an intermediary medium to detect COVID-19 renal effects. Instead of directly analyzing kidney tissue through biopsies or autopsies, the system uses urine molecular fingerprints as a non-invasive proxy that reflects renal viral infection and metabolic changes, thereby improving diagnostic accessibility while maintaining detection precision through advanced spectral analysis.
2Reliability
If invasive methods like renal biopsies are used to detect viral infection, then detection reliability is improved, but patient comfort and procedural complexity are worsened
Solution Approach 1:
The patent inverts the traditional diagnostic approach by moving from direct kidney tissue analysis (invasive biopsy) to analysis of urine metabolites (non-invasive). This inversion maintains detection reliability by capturing viral infection effects on renal function through metabolic changes in urine, while completely eliminating the discomfort and risks associated with invasive procedures.
Solution Approach 2:
The patent enables the body to provide its own diagnostic sample (urine) without requiring external intervention into the kidney tissue. The renal effects of viral infection naturally manifest in urine composition, allowing the patient's own physiological processes to generate the diagnostic material, thereby improving comfort while maintaining reliability through analysis of these self-produced biomarkers.
3Measurement precision
If multiple validation methods are used to confirm renal viral infection, then diagnostic accuracy is improved, but device complexity and time consumption are worsened
Solution Approach 1:
The patent makes Raman spectroscopy a universal diagnostic tool that can simultaneously detect multiple aspects of COVID-19 renal effects through a single analytical platform. The technique provides comprehensive molecular fingerprinting of urine samples, capturing viral infection markers, metabolic changes, and renal function indicators in one test, thereby maintaining high diagnostic accuracy while reducing the need for multiple separate validation methods.
Solution Approach 2:
The patent transforms the diagnostic approach by changing the measurement parameters from direct viral detection (requiring multiple methods like immunohistochemistry, RT-PCR, in situ hybridization) to detection of metabolic parameter changes in urine. By monitoring shifts in molecular composition and metabolic profiles through Raman spectroscopy, the system achieves high diagnostic accuracy through a unified method that tracks physiological responses to viral infection.
Data Source
AI summary
The present invention comprises methods of detecting and classifying COVID-19 disease using Raman spectra obtained from subject urine samples. Raman spectra from subject urine samples are analyzed using models prepared from reference Raman samples obtained from urine samples of individuals with and without COVID-19. The spectral fingerprints of urine from subjects with and without COVID-19 allow for identification of disease-associated changes in urine molecular composition.